In a type 2 diabetes (T2D) model, MPTP treatment upregulates the level of oligomeric α-syn in both pancreas and midbrain, resulting in increased IL-1β secretion via NLRP3 activation, and ultimately exacerbates the loss of DA neurons [65]. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.